Collectively, these results indicate that METTL3-mediated m6A modifications regulate candidate gene expression in a cell line-specific manner and modulate the antitumor immune response, underscoring the potential of targeting METTL3 in NSCLC therapy. Here, METTL3 is linked to non-small cell lung carcinoma.